Muscular Dystrophy Canada fund nine new projects through 2023 grant program
NMD4C Investigators involved in many of these exciting clinical and translational research projects
On Thursday March 30th, Muscular Dystrophy Canada (MDC) announced the results of their 2023 Neuromuscular Clinical and Translational Research Grant Program. A dedicated Canadian source of funding for neuromuscular research, this annual funding competition invests in clinical and translational research projects related to the diagnosis, treatment, or clinical care of neuromuscular disorders. These research grants help fill current gaps in the funding landscape.
This year we are pleased to celebrate the many NMD4C investigators and members who are leading and supporting MDC-funded projects! You can find the full list of funded projects on MDC’s website.
2023 Clinical Research Projects
Establishing the Top Ten Research Priorities for Respiratory Care of Childhood Neuromuscular Disorders ($50,000)
NMD4C investigators and collaborators as project co-investigators and collaborators
Dietary Protein Requirements in Adults with Muscular Dystrophy ($100,000)
Project Lead
Dr Tyler Churchward-Venne
McGill University
NMD4C member as project co-investigator
Dr Mark Tarnopolsky
Muscle MRI in neuromuscular disorders. The era of Artificial Intelligence ($100,000)
NMD4C investigator as project collaborator
B-FIT! Taking exercise away from the hospital into the home environment in people with Oculopharyngeal muscular dystrophy ($100,000)
Project Lead
Dr Eric Voorn
University of Amsterdam
NMD4C investigators and members as project co-investigators and collaborators
Reimagining Rehabilitation for SMA: Patient and Family Perspectives ($83,166)
Project Lead
Dr Jill Glennis Zwicker
University of British Columbia
NMD4C investigators and members as project co-investigators and collaborators
Translational Research Grants
Therapy development for centronuclear myopathy caused by DNM2 gene changes ($100,000)
How genealogies (family histories) can help us understand myotonic dystrophy type 1 ($99,600)
Project Lead
Dr Simon Girard
Université du Québec à Chicoutimi
NMD4C investigators as project co-investigators
Evaluating the impact of stop variants on MLIP’s (Muscular LMNA-Interacting Protein) function in muscle ($100, 000)
Pre-clinical testing of novel pharmacological inhibitors of toxic DMPK mRNA in models of myotonic dystrophy type 1 ($100 000)
Project Lead
Dr Pascal Chartrand
University of Montreal
Read next...
NMD4C to Develop a List of Canadian Neuromuscular Research Labs to Support Research Collaborations and Training
We are excited to launch an initiative from the NMD4C cell and animal-based NMD research tasks to develop a centralized list of Canadian neuromuscular research labs, and we need your help to collect this information!
MDC and NMD4C Hiring Full-Time Clinical Trials and Community Practice Manager
Join our team of dedicated colleagues and volunteers in breaking down barriers for the neuromuscular community and help bring clinical trials to Canada!
Annual NMD4C Early-Career Awards Program Accepting Applications
We are excited to launch the second year of the NMD4C Early-Career Awards for 2024!
NMD4C Pre-clinical Science Pillar Seeking Trainee Input
The NMD4C cell and animal-based research team is actively seeking the input of neuromuscular trainees to help inform our activities. If you are willing to participate in a committee that will meet periodically to share input on NMD4C cell and animal-based research activities, we want to hear from you!
NMD4C Investigators Dr Rashmi Kothary and Dr Natasha Chang Receive MDC Awards
We are excited to share that NMD4C investigators Dr Rashmi Kothary, and Dr Natasha Chang received the Dr George Karpati Award for Researcher of the Year and Rising Clinician/Researcher Award respectively from Muscular Dystrophy Canada
Vamorolone receives approval by the FDA in the US and positive opinion from CHMP in the EU for use in the treatment of Duchenne muscular dystrophy.
The FDA approved vamorolone on October 26, 2023 for the treatment of DMD in the US, while the CHMP has issued a positive opinion for vamorolone for the treatment of DMD in the EU.